GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » ABL Diagnostics (XPAR:ABLD) » Definitions » Net Cash per Share

ABL Diagnostics (XPAR:ABLD) Net Cash per Share : €-0.50 (As of Jun. 2023)


View and export this data going back to 1989. Start your Free Trial

What is ABL Diagnostics Net Cash per Share?

Net Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities minus Total Liabilities minus Minority Interest and then divided by Shares Outstanding (EOP). ABL Diagnostics's Net Cash per Share for the quarter that ended in Jun. 2023 was €-0.50.

The historical rank and industry rank for ABL Diagnostics's Net Cash per Share or its related term are showing as below:

During the past 13 years, the highest Price-to-Net-Cash Ratio of ABL Diagnostics was 9.69. The lowest was 1.12. And the median was 1.64.

XPAR:ABLD's Price-to-Net-Cash is not ranked *
in the Healthcare Providers & Services industry.
Industry Median: 8.27
* Ranked among companies with meaningful Price-to-Net-Cash only.

ABL Diagnostics Net Cash per Share Historical Data

The historical data trend for ABL Diagnostics's Net Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ABL Diagnostics Net Cash per Share Chart

ABL Diagnostics Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Net Cash per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.32 3.41 1.17 1.30 -0.47

ABL Diagnostics Semi-Annual Data
Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
Net Cash per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.32 1.30 1.20 -0.47 -0.50

Competitive Comparison of ABL Diagnostics's Net Cash per Share

For the Health Information Services subindustry, ABL Diagnostics's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ABL Diagnostics's Price-to-Net-Cash Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, ABL Diagnostics's Price-to-Net-Cash distribution charts can be found below:

* The bar in red indicates where ABL Diagnostics's Price-to-Net-Cash falls into.



ABL Diagnostics Net Cash per Share Calculation

In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.

ABL Diagnostics's Net Cash per Share for the fiscal year that ended in Dec. 2022 is calculated as

Net Cash per Share (A: Dec. 2022 )
=(Cash, Cash Equivalents, Marketable Securities-Total Liabilities-Minority Interest)/Shares Outstanding (EOP)
=(1.013-8.654-0)/16.1139
=-0.47

ABL Diagnostics's Net Cash per Share for the quarter that ended in Jun. 2023 is calculated as

Net Cash per Share (Q: Jun. 2023 )
=(Cash, Cash Equivalents, Marketable Securities-Total Liabilities-Minority Interest)/Shares Outstanding (EOP)
=(1.545-9.661-0)/16.1139
=-0.50

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ABL Diagnostics  (XPAR:ABLD) Net Cash per Share Explanation

Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.


ABL Diagnostics Net Cash per Share Related Terms

Thank you for viewing the detailed overview of ABL Diagnostics's Net Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


ABL Diagnostics (XPAR:ABLD) Business Description

Traded in Other Exchanges
N/A
Address
72c, rue de, WOIPPY, Thionville, FRA, 57140
ABL Diagnostics is a diagnostic and medical software company. The group has focused on the development of software for collecting and processing medical databases, measuring the quality of care, diagnosing infectious diseases by genotyping, and providing decision support for doctors and nurses, virology and microbiology laboratories, and researchers dealing with patients suffering from chronic and complex diseases. It also develops, manufactures, and markets kits for clinical specimen collection.

ABL Diagnostics (XPAR:ABLD) Headlines

No Headlines